Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "Omission of Breast Surgery After Neoadjuvant Systemic Therapy for Invasive Cancer - 3-Year Preplanned Primary-Endpoint on a Phase 2 Multicentre Prospective Trial"

647 views
October 26, 2023
Comments 1
Login to view comments. Click here to Login